Sona Nanotech Touts "Superior" Results from Animal Study for Cancer Therapy, Eyes In-human Study
Sona Nanotech (CSE:SONA,OTCQB:SNANF) is ramping up clinical trials for its targeted hyperthermia therapy (THT) for cancer. CEO David Regan said the company is looking forward to taking THT into in-human studies after interim results from its efficacy study on animals showed statistically significantly superior results. “We went into this study with a simple hypothesis that our THT for cancer would shrink cells and … tumors from the inside out … But we found something more interesting along the way,” he said. “We've seen in this study it’s not just that the treated tumor shrinks, but that you'r...